Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF +2.06%69 3-Year EPS without NRI Growth Rate is 0.50% as of Mar. 2026, which is 76% below its 10-year median of 2.10. GuruFocus rates PROF with a GF Scoreâ„¢ of 69/100 and a GF Valueâ„¢ of $14.73 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 661 Medical Devices & Instruments companies, Profound Medical ranks worse than 60.97% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 0.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -3.00% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Profound Medical was 35.50% per year. The lowest was -6.80% per year. And the median was 2.10% per year.
Profound Medical (NAS:PROF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Profound Medical 3-Year EPS without NRI Growth Rate Related Terms
PROF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Profound Medical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Profound Medical's 3-Year EPS without NRI Growth Rate falls into.
Profound Medical 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.50% mean?
Profound Medical (PROF) has a 3-Year EPS without NRI Growth Rate of 0.50% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Profound Medical and its competitors. This is 76% below median its historical median of 2.10. According to the industry distribution chart, Profound Medical ranks #403 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 61%.
Is Profound Medical's 3-Year EPS without NRI Growth Rate too high?
Profound Medical's current 3-Year EPS without NRI Growth Rate of 0.50% is 76% below median its 10-year median of 2.10. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.20. Profound Medical's value of 0.50% is 93.9% below this industry median. Based on the distribution chart, Profound Medical ranks #403 out of 661 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Scoreâ„¢ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #403 out of 661 companies for 3-Year EPS without NRI Growth Rate. This places Profound Medical in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.20. Profound Medical's value of 0.50% is 93.9% below this benchmark. While the company's 10-year median is 2.10 vs. the industry median of 8.20, Profound Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.20, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current 3-Year EPS without NRI Growth Rate of 0.50% is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current 3-Year EPS without NRI Growth Rate is 0.50%, which is 76% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.73, compared to a current price of $6.95 — trading 52.8% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.50%, which is 76% below median its 10-year median of 2.10 and 93.9% below the Medical Devices & Instruments industry median of 8.20. Profound Medical's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Profound Medical (PROF), the current 3-Year EPS without NRI Growth Rate is 0.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $6.95 is trading 52.8% below its estimated GF Value™ of $14.73.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
3-Year EPS without NRI Growth Rate: 0.50% (76% below median its 10-year median of 2.10)
GF Value™: $14.73 vs. price of $6.95 (52.8% below fair value)
Industry Position: 93.9% below the Medical Devices & Instruments median (#403 of 661)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
69GF Score
Get the complete analysis for PROF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
